Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Receivables (2019 - 2025)

Seres Therapeutics (MCRB) has disclosed Change in Receivables for 6 consecutive years, with -$351000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables changed N/A to -$351000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $351000.0 through Sep 2025, up 102.08% year-over-year, with the annual reading at -$8.7 million for FY2024, 200.0% down from the prior year.
  • Change in Receivables hit -$351000.0 in Q4 2025 for Seres Therapeutics, down from $351000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $11.2 million in Q2 2024 to a low of -$18.6 million in Q3 2024.
  • Historically, Change in Receivables has averaged -$782250.0 across 4 years, with a median of -$800500.0 in 2021.
  • Biggest five-year swings in Change in Receivables: tumbled 2962.03% in 2021 and later skyrocketed 101.89% in 2025.
  • Year by year, Change in Receivables stood at -$1.2 million in 2021, then tumbled by 554.64% to -$8.2 million in 2023, then tumbled by 127.31% to -$18.6 million in 2024, then soared by 98.11% to -$351000.0 in 2025.
  • Business Quant data shows Change in Receivables for MCRB at -$351000.0 in Q4 2025, $351000.0 in Q3 2025, and -$18.6 million in Q3 2024.